The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice.

ABSTRACT:

Background

Trials have demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues have limited their use in community practice.

Objective

The aim of the study was to better understand patients' experiences when trying to obtain, fill, and use PCSK9 inhibitor therapy in community practice.

Methods

We conducted a patient survey to evaluate patient experiences with PCSK9 inhibitors including medication initiation, indication for treatment, insurance approval status, medication persistence, and reason for discontinuation. The survey was emailed to 4740 adults who used a patient access support program.

Results

Overall, 1327 of 4740 adults completed the survey (28.0% res

SUBMITTER: Bradley CK 

PROVIDER: S-EPMC7376543 | biostudies-literature | 2019 Sep - Oct

REPOSITORIES: biostudies-literature